Updated Pew Pipeline analysis of both traditional and non-traditional antimicrobial agents in development

Dear All:

To start the new year, I’ve learned that Pew has updated their pipeline analysis. First released in Feb 2014, it has been steadily updated ever since. This newest analysis has a data cut-off of Sep 2017 and covers both traditional antibiotics as well as non-traditional products. All the links you need are just below my signature, but let me point out a few highlights:

  • Separate commentaries are provided on the state of the traditional and non-traditional pipeline.
  • An excellent infographic is provided. Here’s a little piece of it. Combined with the idea that at most 1 in 5 of these products will reach registration, you have a very scary story indeed
Picture
  • As you know, WHO has also recently published a pipeline analysis. The two analyses are complementary and we have a joint blog from the organizations.
  • Pew’s analysis extends that of WHO by covering non-traditional products such as vaccines, microbiome products, immune enhancers, and more. There are 32 of these underway right now. As these are challenging and high-risk products to develop, I am glad to see this level of effort.
  • If you are interested in doing your own analytics, note that the pipeline charts are interactive and can be sorted by development phase, drug class, pathogen coverage, and more. You can also download past versions of the pipeline tables.

Core message: We have a pipeline, but it remains VERY thin. Let’s all get busy and see what can be developed to address the problem of antibiotic resistance!

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Pew’s Dec 2017 Traditional/Small Molecule Antibiotics Analyses

Pew’s Dec 2017 Nontraditional Products Analyses

Upcoming meetings of interest to the AMR community:

Share

Fireside Chat with BARDA’s Branch Chief for Antimicrobials

Note: Be sure to take advantage of the BARDA Industry Day(s) event that occurs Monday-Tuesday of this coming week … see newsletter and forward calendar for details. Dear All, In what could be called Part 2 of Excellent 2023 ASM/ESCMID Talks (read the newsletter on Jen Cohen’s talk on how manufacturing underpins both access and

Japan Pulls for Pandemic Preparedness: Nikkei FT Conference

Dear All, As we discussed in the 5 Nov 2023 “Pulling for Pandemic Preparedness” newsletter, AMR is a global threat: resistance in one part of the world can suddenly appear in your hospital. As an example of that sort of threat, Jason Gale’s 30 Oct 2023 newsletter entitled “Untreatable Typhoid Should Make You Worry About Poop”

Pulling for Pandemic Preparedness

Dear All, This evening I’d like to bring together several relatively recent reports and note how all of them focus in one way or another on Pulling for Pandemic Preparedness … perhaps we can call this the Rule of 3 Ps. And as an aside, I’ll note that I learned the Rule of 4 Ps

PACE: A new £30m fund for AMR innovation

Dear All, Exciting additional news merits two newsletters in one day! I’ll keep it brief and quote directly from the website: “Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced

Scroll to Top